Grade: F — Major Red Flags
Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles
Data: SEC EDGAR 10-K (Filed 2026-02-18, FY ended December 31, 2025) + Yahoo Finance
Auditor: KPMG LLP — Unqualified opinion
One-line verdict: Occidental's cash flow quality is exceptional — CFFO/NI of 4.53x with negative accruals — but the single red flag that triggers the F grade is the critical C4 check: $2.0B cash covers only 8% of $23.4B total debt. The company is aggressively deleveraging (repaying "$4.0 billion of debt" in FY2025 with "an additional $5.4 billion" post-year-end from the OxyChem divestiture), which means the balance sheet at filing date is materially better than year-end numbers show. Net income fell 24% to $2.3B on lower crude prices, but operating cash flow of $10.5B remained robust due to high DD&A and noncash charges typical of E&P companies. The M-Score of -2.90 is clean. The real risk is the $334M Gulf of America well impairment and Berkshire Hathaway's preferred stock overhang with its $800M+ annual dividend obligation.
| Metric | Result |
|---|---|
| ❌ Red Flags | **1** (Cash covers 8% of $23.4B debt — but post-year-end debt repayment of $5.4B improves this) |
| ⚠️ Watch Items | **0** |
| Checks Completed | **18/18** |
| Beneish M-Score | **-2.90** (clean; well below -2.22) |
| Auditor | KPMG LLP — Unqualified opinion |
Three Segments, One Dominant Driver
OXY operates through Oil and Gas (primarily Permian Basin), Midstream and Marketing (including Western Midstream Partners, its MLP), and Chemical (OxyChem, divested post-year-end). Per the 10-K, "an Occidental subsidiary, Western Midstream Holdings, LLC, acts as the general partner of WES, a publicly traded master limited partnership."
The filing discloses a major strategic shift: "In 2025, the Company invested $5.6 billion in high-return oil and gas assets" while simultaneously preparing to divest OxyChem and using proceeds for debt reduction. Capital expenditures guidance for 2026 is "$5.5 billion to $5.9 billion."
Key Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Trend |
|---|---|---|---|---|---|
| Revenue | $36.6B | $23.2B | $22.0B | $21.6B | Post-boom normalization |
| Net Income | $13.3B | $4.7B | $3.1B | $2.3B | Declining with commodity prices |
| Gross Margin | 48.2% | 36.4% | 37.7% | 34.9% | Compressing |
| Net Margin | 36.3% | 20.3% | 13.9% | 10.8% | Sharply lower |
| ROE | 44.2% | 15.5% | 8.9% | 6.5% | CrownRock acquisition diluted equity |
| CFFO/NI | 1.26x | 2.62x | 3.74x | 4.53x | Extreme cash conversion |
The widening gap between CFFO and net income (4.53x) is not a red flag for an E&P company — it reflects massive DD&A charges on the expanded asset base from the CrownRock acquisition. This is actually a sign of accounting conservatism: high noncash charges depress reported earnings while cash continues to flow.
Cash Flow: Deleveraging at Speed
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating Cash Flow | $16.8B | $12.3B | $11.4B | $10.5B |
| CapEx | $4.5B | $5.7B | $6.3B | $6.4B |
| Free Cash Flow | $12.3B | $6.6B | $5.2B | $4.1B |
| Debt Repaid | — | — | — | $4.0B |
| Cash Balance | $984M | $1.4B | $2.1B | $2.0B |
Per the 10-K: "In 2025, the Company used proceeds from divestitures and cash on hand to repay approximately $4.0 billion of debt. Subsequent to December 31, 2025, but before the date of this filing, the Company used proceeds from the OxyChem Transaction to pay or satisfy and discharge an additional $5.4 billion of debt." This means total debt has been reduced by approximately $9.4B from the year-end figure of $23.4B, bringing it closer to $14B at filing date.
The 18-Point Screening
Revenue Quality
| # | Check | Result | Detail |
|---|---|---|---|
| A1 | DSO Change | ✅ Pass | DSO 44 days, -4 days YoY — improving |
| A2 | AR vs Revenue Growth | ✅ Pass | AR -9.3% vs revenue -1.9% — AR shrinking faster |
| A3 | Revenue vs CFFO | ✅ Pass | Revenue -1.9%, CFFO -7.9% — cash tracking revenue |
Expense Quality
| # | Check | Result | Detail |
|---|---|---|---|
| B1 | Inventory vs COGS | ✅ Pass | Inventory +3.8% vs COGS +2.3% — normal |
| B2 | CapEx vs Revenue | ✅ Pass | CapEx +2.6% vs revenue -1.9% — proportional |
| B3 | SG&A Ratio | ✅ Pass | SG&A/Gross Profit 13.1% — excellent |
| B4 | Gross Margin | ✅ Pass | Gross margin 34.9%, -2.7pp — stable for E&P |
Cash Flow Quality
| # | Check | Result | Detail |
|---|---|---|---|
| C1 | CFFO vs Net Income | ✅ Pass | CFFO/NI 4.53x — extreme cash conversion (DD&A driven) |
| C2 | Free Cash Flow | ✅ Pass | FCF $4.1B, FCF/NI 1.76x |
| C3 | Accruals Ratio | ✅ Pass | Accruals ratio -9.7% — deeply negative, very clean |
| C4 | Cash vs Debt | ❌ Fail | Cash $2.0B covers 8% of $23.4B debt |
Balance Sheet Quality
| # | Check | Result | Detail |
|---|---|---|---|
| D1 | Goodwill + Intangibles | ✅ Pass | No goodwill — clean balance sheet |
| D2 | Leverage | ✅ Pass | Debt/EBITDA 2.0x, interest coverage 3.4x |
| D3 | Soft Asset Growth | ✅ Pass | Other assets +17.2% vs revenue -1.9% — normal |
| D4 | Asset Impairment | ✅ Pass | Write-offs normal |
Acquisition Risk
| # | Check | Result | Detail |
|---|---|---|---|
| E1 | Serial Acquirer FCF | ✅ Pass | FCF after acquisitions positive |
| E2 | Goodwill Surge | ✅ Pass | No goodwill |
Manipulation Score
| # | Check | Result | Detail |
|---|---|---|---|
| F1 | Beneish M-Score | ✅ Pass | M-Score -2.90 — unlikely manipulator |
Altman Z-Score: 1.93 (grey zone) | F-Score: 0.44 (low manipulation probability 0.16%)
Key Risks from the 10-K
Summary
OXY's F grade is mechanically triggered by the C4 critical check — cash covering only 8% of debt. However, this is one of those cases where the grade overstates the actual risk: the company repaid $9.4B of debt between year-end and the filing date, the M-Score is clean at -2.90, cash flow quality is exceptional (accruals ratio -9.7%, CFFO/NI 4.53x), and zero goodwill means no impairment landmines beyond the disclosed Gulf of America wells. The Z-Score of 1.93 sits in the grey zone but will likely move to safe territory once post-year-end debt repayments are reflected. The real risk for investors is not accounting fraud but commodity price exposure in a post-OxyChem, more concentrated E&P business.
